ライフサイエンスコーパス: combination antiretroviral therapy

1 sible in vivo, especially in the presence of combination antiretroviral therapy.

2 human immunodeficiency virus (HIV) receiving combination antiretroviral therapy.

3 morbidity among people with HIV/AIDS taking combination antiretroviral therapy.

4 infection can now be readily controlled with combination antiretroviral therapy.

5 ery other week for 8 weeks while maintaining combination antiretroviral therapy.

6 group of HIV-infected individuals undergoing combination antiretroviral therapy.

7 symptomatic HIV-infected subjects undergoing combination antiretroviral therapy.

8 isease, in spite of the notable successes of combination antiretroviral therapy.

9 le with those measured in patients receiving combination antiretroviral therapy.

10 y, despite success reducing viral loads with combination antiretroviral therapy.

11 the end of 1995, before the introduction of combination antiretroviral therapy.

12 level, and over time, both before and during combination antiretroviral therapy.

13 t a majority of patients treated with potent combination antiretroviral therapy.

14 ded to address the question of when to begin combination antiretroviral therapy.

15 immunotherapy of HIV-1-infected patients on combination antiretroviral therapy.

16 7 was identified in a patient who had failed combination antiretroviral therapy.

17 V)-infected individuals who are treated with combination antiretroviral therapy.

18 barrier to virus eradication in patients on combination antiretroviral therapy.

19 enous and exogenous T-cell progenitors after combination antiretroviral therapy.

20 patients, the cysts resolved completely with combination antiretroviral therapy.

21 ts, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy.

22 ral load and were receiving TDF as a part of combination antiretroviral therapy.

23 ven in the setting of viral suppression with combination antiretroviral therapy.

24 sub-Saharan Africa and 96.8% were receiving combination antiretroviral therapy.

25 vailable for use by HIV-1 and is now used in combination antiretroviral therapy.

26 ation, remarkably with potency equivalent to combination antiretroviral therapy.

27 an age was 47.3 years and 98% were receiving combination antiretroviral therapy.

28 1 years), 78% of participants were receiving combination antiretroviral therapy, 41% had a CD4(+) cel

29 rtality may, in part, stem from wider use of combination antiretroviral therapy, 622 HIV-positive men

30 Combination antiretroviral therapy administered well aft

31 ug resistance incidence to modern first-line combination antiretroviral therapies against human immun

32 enerally prevents cure of the infection with combination antiretroviral therapy alone.

33 Volunteers with HIV who were undergoing combination antiretroviral therapy and age-matched contr

34 To determine the relationship of combination antiretroviral therapy and bacterial pneumon

35 tively evaluated 16 HIV-infected patients on combination antiretroviral therapy and eight healthy con

36 athy in HIV infection is not eliminated with combination antiretroviral therapy and is possibly linke

37 of infectious HIV-1 persist despite years of combination antiretroviral therapy and make curing HIV-1

38 The introduction of combination antiretroviral therapy and protease inhibito

39 symptoms resolved completely after starting combination antiretroviral therapy and remain subsided f

40 With the advent of combination antiretroviral therapy and the development o

41 ants with 52 women who did not; 33% received combination antiretroviral therapy, and 65% received mon

42 during a time of widespread availability of combination antiretroviral therapy, and mortality is rea

43 ensive care unit has decreased in the era of combination antiretroviral therapy, and patients are mor

44 ency virus (HIV)-infected (HIV+) patients on combination antiretroviral therapy are living longer but

45 erm clinical trials of BMS-663068 as part of combination antiretroviral therapy are warranted.

46 Early potent combination antiretroviral therapies (ART) for HIV-1 inf

47 Combination antiretroviral therapy (ART) can suppress pl

48 ients with virological failure of first-line combination antiretroviral therapy (ART) containing the

49 The benefits of combination antiretroviral therapy (ART) for HIV cogniti

50 Combination antiretroviral therapy (ART) for HIV-1 infec

51 Combination antiretroviral therapy (ART) has had a major

52 PURPOSE OF REVIEW: Combination antiretroviral therapy (ART) has turned HIV

53 d for patients infected with HIV-1 who start combination antiretroviral therapy (ART) in high-income

54 We find that, as in humans, combination antiretroviral therapy (ART) in humanized (h

55 HIV), but patterns of cancer incidence after combination antiretroviral therapy (ART) initiation rema

56 Combination antiretroviral therapy (ART) is able to supp

57 Access to combination antiretroviral therapy (ART) is expanding in

58 Although lifelong combination antiretroviral therapy (ART) is recommended

59 CD4 count at start of combination antiretroviral therapy (ART) is strongly ass

60 in Africa; whether benefits occur alongside combination antiretroviral therapy (ART) is unclear.

61 We analysed the effect of immediate combination antiretroviral therapy (ART) on viraemia and

62 It remains unclear to what degree combination antiretroviral therapy (ART) protects agains

63 As widespread adoption of potent combination antiretroviral therapy (ART) reaches its ten

64 t the median age of HIV-infected patients on combination antiretroviral therapy (ART) will increase f

65 Combination antiretroviral therapy (ART), also known as

66 factors, including immunosuppression, use of combination antiretroviral therapy (ART), and injecting

67 cohort in Baltimore, we compared receipt of combination antiretroviral therapy (ART), HIV type 1 (HI

68 The bar is high to improve on current combination antiretroviral therapy (ART), now highly eff

69 n, allowing patients to discontinue lifelong combination antiretroviral therapy (ART).

70 een systematically studied during the era of combination antiretroviral therapy (ART).

71 t challenges to realize the full benefits of combination antiretroviral therapy (ART).

72 converters and 376 with viral suppression on combination antiretroviral therapy (ART).

73 eatment experienced (ie, with >/=9 months on combination antiretroviral therapy [ART] and at risk of

74 ntituberculous therapy and subsequently with combination antiretroviral therapy (ARV), we conducted a

75 The introduction of combination antiretroviral therapy as the standard of ca

76 Access to combination antiretroviral therapy, as well as health re

77 ts, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy at enrollment.

78 ase decreased significantly after 1997, when combination antiretroviral therapy became widely availab

79 the CASCADE collaboration, since 1997, when combination antiretroviral therapy became widely availab

80 tegrated Clinical Systems site who initiated combination antiretroviral therapy between 1 January 200

81 ficiency syndrome (AIDS) after initiation of combination antiretroviral therapy between 1998 and 2012

82 mmunodeficiency virus (HIV) replication with combination antiretroviral therapy, both HIV and chronic

83 We observed that irrespective of combination antiretroviral therapy, both short- and long

84 ential novel therapeutic approach to enhance combination antiretroviral therapy by suppressing hyperi

85 Although combination antiretroviral therapy can dramatically redu

86 Although potent combination antiretroviral therapy can effectively block

87 Combination antiretroviral therapy can markedly suppress

88 human immunodeficiency virus type 1 (HIV-1), combination antiretroviral therapy can result in sustain

89 Combination antiretroviral therapy can suppress human im

90 Combination antiretroviral therapies (cART) are clearly

91 Combination antiretroviral therapy (cART) administered s

92 Antiretroviral-naive individuals initiating combination antiretroviral therapy (cART) after 1 Januar

93 Present combination antiretroviral therapy (cART) alone does not

94 uction in 20 HIV-infected patients receiving combination antiretroviral therapy (cART) and 2 groups o

95 As a result of effective combination antiretroviral therapy (cART) and advanced s

96 mmune activation persist after initiation of combination antiretroviral therapy (cART) and HIV suppre

97 Our objective was to determine the impact of combination antiretroviral therapy (cART) and the degree

98 nitis in patients with AIDS after initiating combination antiretroviral therapy (cART) and the role o

99 n addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy (cART) and to compare

100 th treated cryptococcal meningitis who start combination antiretroviral therapy (cART) are at risk of

101 us type 1 (HIV-1)-infected infant started on combination antiretroviral therapy (cART) at 30 hours of

102 ency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing ten

103 Decisions regarding whether to start combination antiretroviral therapy (cART) during primary

104 Combination antiretroviral therapy (cART) effectively bl

105 Combination antiretroviral therapy (cART) effectively co

106 atient.IMPORTANCE HIV patients who interrupt combination antiretroviral therapy (cART) eventually exp

107 Combination antiretroviral therapy (cART) generally supp

108 Combination antiretroviral therapy (cART) has been shown

109 s (HIV)-infected children and adolescents on combination antiretroviral therapy (cART) has not been c

110 Combination antiretroviral therapy (cART) has reduced HI

111 Combination antiretroviral therapy (cART) has resulted i

112 The advent of combination antiretroviral therapy (cART) has significan

113 wn that NK cells from HIV patients receiving combination antiretroviral therapy (cART) have decreased

114 omen receiving protease inhibitor (PI)-based combination antiretroviral therapy (cART) have lower lev

115 (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral therapy (cART) impacted stead

116 s were quantified during long-term effective combination antiretroviral therapy (cART) in 4 perinatal

117 s type 1 (HIV-1)-infected cells during early combination antiretroviral therapy (cART) in infected in

118 We included HIV+ individuals who started combination antiretroviral therapy (cART) in the Veteran

119 inflammatory syndrome (TB-IRIS) complicates combination antiretroviral therapy (cART) in up to 25% o

120 virologic failure (VF) of initial NVP-based combination antiretroviral therapy (cART) in women with

121 munodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cART) incorporating

122 Mortality rates within the first year of combination antiretroviral therapy (cART) initiation are

123 e studies assessing treatment outcomes after combination antiretroviral therapy (cART) initiation in

124 etroviral Treatment (START) study, immediate combination antiretroviral therapy (cART) initiation red

125 Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administere

126 We evaluated whether suboptimal adherence to combination antiretroviral therapy (cART) is associated

127 idual infected cells are present at the time combination antiretroviral therapy (cART) is discontinue

128 e 1 (HIV-1) reservoirs in patients receiving combination antiretroviral therapy (cART) is largely unk

129 Combination antiretroviral therapy (cART) is standard of

130 infection, traditional CKD risk factors, and combination antiretroviral therapy (cART) may all contri

131 Human immunodeficiency virus (HIV) and combination antiretroviral therapy (cART) may both contr

132 Studies analyzing the impact of combination antiretroviral therapy (cART) on cervical in

133 thymic function and CD4 T-cell dynamics and combination antiretroviral therapy (cART) onset were ana

134 the majority of patients receiving long-term combination antiretroviral therapy (cART) present with C

135 infected cells in individuals on suppressive combination antiretroviral therapy (cART) presents a maj

136 fection, and whether immediate initiation of combination antiretroviral therapy (cART) prevents neuro

137 Combination antiretroviral therapy (cART) reduces genita

138 The treatment of AIDS with combination antiretroviral therapy (cART) remains lifelo

139 ed sex act with an HIV-infected person under combination antiretroviral therapy (cART) remains unknow

140 eficiency virus (HIV)-infected children with combination antiretroviral therapy (cART) requires asses

141 Combination antiretroviral therapy (cART) suppresses pla

142 2% in the UK and 60% in the USA) to initiate combination antiretroviral therapy (cART) than other HIV

143 pecifically restored T cell reactivity after combination antiretroviral therapy (cART) to early infec

144 Early initiation of combination antiretroviral therapy (cART) to human immun

145 After the success of combination antiretroviral therapy (cART) to treat HIV i

146 Metabolic effects following combination antiretroviral therapy (cART) vary by regime

147 30 SIV-infected pigtailed macaques receiving combination antiretroviral therapy (cART) was conducted.

148 Sustained combination antiretroviral therapy (cART) was defined as

149 esistance testing (GRT) in patients for whom combination antiretroviral therapy (cART) was unsuccessf

150 Patients on combination antiretroviral therapy (cART) were randomize

151 virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 c

152 ematically recommended for mothers receiving combination antiretroviral therapy (cART) with low viral

153 eir association with number of vaccinations, combination antiretroviral therapy (cART), and HIV statu

154 btype B, no indication for immediate need of combination antiretroviral therapy (cART), and sufficien

155 ssociated with outcomes of HIV infection and combination antiretroviral therapy (CART), and with neur

156 L-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL1

157 us (HIV; PLWH) who are receiving suppressive combination antiretroviral therapy (cART), but their pat

158 able to HIV-1.SIGNIFICANCE STATEMENT Despite combination antiretroviral therapy (cART), neurocognitiv

159 Before the introduction of combination antiretroviral therapy (cART), patients infe

160 Before the advent of combination antiretroviral therapy (cART), roughly 50% o

161 ected men who have sex with men (MSM) taking combination antiretroviral therapy (cART), the impact of

162 -RNA levels <40 copies per milliliter during combination antiretroviral therapy (cART), the majority

163 Despite immune reconstitution with combination antiretroviral therapy (cART), there was no

164 ronically infected with HIV-1 that initiated combination antiretroviral therapy (cART).

165 ust have HIV infection that is responsive to combination antiretroviral therapy (cART).

166 ated cryptococcal meningitis (CM) commencing combination antiretroviral therapy (cART).

167 rm virological suppression during receipt of combination antiretroviral therapy (cART).

168 We also analyzed effects of initiating combination antiretroviral therapy (cART).

169 impairment remains frequent in HIV, despite combination antiretroviral therapy (cART).

170 ) T cells that is only partially reversed by combination antiretroviral therapy (cART).

171 ntrolled viral load and restored immunity on combination antiretroviral therapy (cART).

172 trol HIV infection without a requirement for combination antiretroviral therapy (cART).

173 ich have become more prevalent in the era of combination antiretroviral therapy (cART).

174 reservoir in infected individuals receiving combination antiretroviral therapy (cART).

175 iency virus (HIV)-positive patients starting combination antiretroviral therapy (cART).

176 viral gene expression and effectively resist combination antiretroviral therapy (cART).

177 s after initiation of raltegravir-containing combination antiretroviral therapy (cART).

178 ation of HIV disease in the era of effective combination antiretroviral therapy (cART).

179 ries despite the widespread use of effective combination antiretroviral therapy (cART).

180 (CHER) cohort after 7-8 years of suppressive combination antiretroviral therapy (cART).

181 ically suppressed (VS) individuals receiving combination antiretroviral therapy (cART).

182 be interchangeable components in first-line combination antiretroviral therapy (cART).

183 i sarcoma (KS) incidence has decreased since combination antiretroviral therapy (cART).

184 ells in individuals treated with suppressive combination antiretroviral therapy (cART).

185 Thirty-one (39%) of 80 men (59 prescribed combination antiretroviral therapy [cART]) had HIV detec

186 acterial pneumonia resulting from the use of combination antiretroviral therapy containing protease i

187 Combination antiretroviral therapy during primary HIV-1

188 tantially expanded since the introduction of combination antiretroviral therapy during the HIV epidem

189 drome (AIDS), death, or the beginning of the combination antiretroviral therapy era (January 1, 1996)

190 Indeed, in the combination antiretroviral therapy era, the curability o

191 In many patients, combination antiretroviral therapy fails to achieve comp

192 We have utilized combination antiretroviral therapy following human immun

193 14 patients who were receiving highly active combination antiretroviral therapy for > or =116 weeks w

194 st with indinavir for 16 weeks and then with combination antiretroviral therapy for >2 years.

195 Combination antiretroviral therapy for HIV infection imp

196 Randomised, controlled trial data show that combination antiretroviral therapy for HIV-1 infection b

197 The success of combination antiretroviral therapy for HIV-1 infection h

198 acy of raltegravir with efavirenz as part of combination antiretroviral therapy for treatment-naive p

199 ongoing viral replication in 10 patients on combination antiretroviral therapy for up to 1 year, the

200 for women without advanced disease, lifelong combination antiretroviral therapy for women with advanc

201 Combination antiretroviral therapy has had a major role

202 ncy virus (HIV) infection with highly active combination antiretroviral therapy has increased surviva

203 Combination antiretroviral therapy has substantially inc

204 Although combination antiretroviral therapy has substantially red

205 rse of HIV-infected individuals treated with combination antiretroviral therapy in 4 US cities.

206 d durability of response of newly instituted combination antiretroviral therapy in HIV-1-infected chi

207 Some studies suggest that combination antiretroviral therapy in pregnant women wit

208 Combination antiretroviral therapy initiated during acut

209 Combination antiretroviral therapy initiated within seve

210 Combination antiretroviral therapy is not available thro

211 mulation suggests that earlier initiation of combination antiretroviral therapy is often favored comp

212 been dramatically reduced wherever effective combination antiretroviral therapy is used, there has be

213 We conclude that protease inhibitor use (in combination antiretroviral therapy) is likely to favorab

214 s in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is

215 In recent years, the early initiation of combination antiretroviral therapy leading to virologica

216 Early combination antiretroviral therapy led to a loss of plas

217 The long-term efficacy of combination antiretroviral therapy may relate to augment

218 , CNS penetration effectiveness, duration of combination antiretroviral therapy, medication adherence

219 tients with chronic HIV infection undergoing combination antiretroviral therapy (n=28) and control su

220 9; 30.23%), HIV-infected subjects undergoing combination antiretroviral therapy (n=90; 69.77%) had 47

221 ts are consistent with the notion that early combination antiretroviral therapy of HIV-1-infected inf

222 e men who have sex with men, 78% were taking combination antiretroviral therapy (of whom 86% had an H

223 Concurrent prescription of combination antiretroviral therapy (OR, 0.2) and other a

224 Treg depletion combined with combination antiretroviral therapy provides a novel stra

225 g, compared with the use of empirical triple combination antiretroviral therapy, provides additional

226 Upon initiation of combination antiretroviral therapy, recovery of cellular

227 d States and Europe confirm that full-course combination antiretroviral therapy reduces rates of moth

228 Use of combination antiretroviral therapy regimens, including a

229 analyses were performed to identify HIV- and combination antiretroviral therapy-related factors assoc

230 therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monoth

231 The use of combination antiretroviral therapy results in a substant

232 rse transcriptase inhibitor therapy prior to combination antiretroviral therapy, stavudine exposure w

233 eiving durable (median duration, 10.2 years) combination antiretroviral therapy, stratified by age at

234 that in HIV-infected patients on suppressive combination antiretroviral therapy, such host-derived tr

235 ilar in patients virologically suppressed on combination antiretroviral therapy, suggesting that immu

236 Combination antiretroviral therapies suppress human immu

237 nificant decline of plasma HBV DNA load with combination antiretroviral therapy that contained lamivu

238 iciency virus (HIV)-infected patients taking combination antiretroviral therapy that includes HIV pro

239 imited evidence about longer-term effects of combination antiretroviral therapy that includes proteas

240 With the introduction of combination antiretroviral therapy, the incidence of HIV

241 Although administered within the context of combination antiretroviral therapy, the infection of bys

242 on is living longer, largely attributable to combination antiretroviral therapy, there is concern abo

243 With current efforts to provide earlier combination antiretroviral therapy to HIV-infected peopl

244 Administration of combination antiretroviral therapy to human immunodefici

245 TIs) are recommended components of preferred combination antiretroviral therapies used for the treatm

246 Combination antiretroviral therapy was associated with t

247 t in the epidemic occurred in 1995-1996 when combination antiretroviral therapy was introduced, effec

248 After adjustment for multiple risk factors, combination antiretroviral therapy was not associated wi

249 nts with latency-reversing agents (LRAs) and combination antiretroviral therapy was proposed as a mea

250 Combination antiretroviral therapy was suspended before

251 re December 1997, in Espirito Santo, Brazil, combination antiretroviral therapy was used without rout

252 eline data from 1,053 participants receiving combination antiretroviral therapy who were enrolled in

253 m a HIV-1 elite controller, not treated with combination antiretroviral therapy, who experienced vira

254 Combination antiretroviral therapy with a combination of

255 Combination antiretroviral therapy with indinavir, zidov

256 Early effective combination antiretroviral therapy with prolonged virolo

257 Combination antiretroviral therapy with protease inhibit

258 individuals (n = 17), HIV(+) individuals on combination antiretroviral therapy with viral loads belo

259 These cysts respond to combination antiretroviral therapy, with or without cort

260 een functionally cured of HIV by being given combination antiretroviral therapy within hours of birth